PRECIGEN, INC. Sales Revenue, Services, Net (Deprecated 2018-01-31)
PRECIGEN, INC. (PGEN) reported Sales Revenue, Services, Net (Deprecated 2018-01-31) of $17.72 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueServicesNet · last filed 2018-08-13
- PRECIGEN, INC. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $17.72M, a 11.55% increase year-over-year.
- PRECIGEN, INC. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $12.25M, a 1.80% increase year-over-year.
- PRECIGEN, INC. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $12.72M, a 30.46% increase year-over-year.
- PRECIGEN, INC. sales revenue, services, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $9.97M, a 14.58% increase year-over-year.
- PRECIGEN, INC. sales revenue, services, net (deprecated 2018-01-31) for fiscal 2017 was $50.61M, a 17.57% increase from fiscal 2016.
- PRECIGEN, INC. sales revenue, services, net (deprecated 2018-01-31) for fiscal 2016 was $43.05M, a 0.29% increase from fiscal 2015.
- PRECIGEN, INC. sales revenue, services, net (deprecated 2018-01-31) for fiscal 2015 was $42.92M, a 190.79% increase from fiscal 2014.
- PRECIGEN, INC. sales revenue, services, net (deprecated 2018-01-31) for fiscal 2014 was $14.76M.
| Period end | Sales Revenue, Services, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Services, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-06-30 | $17.72M 10-Q · filed 2018-08-13 | $29.96M 10-Q · filed 2018-08-13 | $42.69M derived: sum of 3 quarters · filed 2018-08-13 | $52.66M derived: sum of 4 quarters · filed 2018-08-13 |
| 2018-03-31 | $12.25M 10-Q/A · filed 2018-08-13 | $24.97M derived: sum of 2 quarters · filed 2018-08-13 | $34.94M derived: sum of 3 quarters · filed 2018-08-13 | $50.83M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-12-31 | $12.72M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $22.70M derived: sum of 2 quarters · filed 2018-03-01 | $38.58M derived: sum of 3 quarters · filed 2018-08-13 | $50.61M 10-K · filed 2018-03-01 |
| 2017-09-30 | $9.97M 10-Q · filed 2017-11-09 | $25.86M derived: sum of 2 quarters · filed 2018-08-13 | $37.89M 10-Q · filed 2017-11-09 | $47.64M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-06-30 | $15.88M 10-Q · filed 2018-08-13 | $27.91M 10-Q · filed 2018-08-13 | $37.67M derived: sum of 3 quarters · filed 2018-08-13 | $46.37M derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-03-31 | $12.03M 10-Q/A · filed 2018-08-13 | $21.78M derived: sum of 2 quarters · filed 2018-08-13 | $30.49M derived: sum of 3 quarters · filed 2018-08-13 | $44.41M derived: sum of 4 quarters · filed 2018-08-13 |
| 2016-12-31 | $9.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $18.46M derived: sum of 2 quarters · filed 2018-03-01 | $32.38M derived: sum of 3 quarters · filed 2018-03-01 | $43.05M 10-K · filed 2018-03-01 |
| 2016-09-30 | $8.71M 10-Q · filed 2017-11-09 | $22.63M derived: sum of 2 quarters · filed 2017-11-09 | $33.30M 10-Q · filed 2017-11-09 | $44.06M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $13.93M 10-Q · filed 2017-08-09 | $24.59M 10-Q · filed 2017-08-09 | $35.36M derived: sum of 3 quarters · filed 2018-03-01 | $44.30M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $10.66M 10-Q · filed 2017-05-10 | $21.43M derived: sum of 2 quarters · filed 2018-03-01 | $30.38M derived: sum of 3 quarters · filed 2018-03-01 | $43.63M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $10.77M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $19.71M derived: sum of 2 quarters · filed 2018-03-01 | $32.97M derived: sum of 3 quarters · filed 2018-03-01 | $42.92M 10-K · filed 2018-03-01 |
| 2015-09-30 | $8.95M 10-Q · filed 2016-11-09 | $22.20M derived: sum of 2 quarters · filed 2016-11-09 | $32.16M 10-Q · filed 2016-11-09 | $42.66M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $13.26M 10-Q · filed 2016-08-09 | $23.21M 10-Q · filed 2016-08-09 | $33.71M derived: sum of 3 quarters · filed 2017-03-01 | $37.97M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $9.96M 10-Q · filed 2016-05-10 | $20.46M derived: sum of 2 quarters · filed 2017-03-01 | $24.72M derived: sum of 3 quarters · filed 2017-03-01 | $24.72M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $14.76M derived: sum of 2 quarters · filed 2017-03-01 | $14.76M derived: sum of 3 quarters · filed 2017-03-01 | $14.76M 10-K · filed 2017-03-01 |
| 2014-09-30 | $4.26M 10-Q · filed 2015-11-09 | $4.26M derived: sum of 2 quarters · filed 2015-11-09 | $4.26M 10-Q · filed 2015-11-09 | $4.26M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $0.00 10-Q · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $0.00 10-Q · filed 2015-05-11 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 | |
| 2013-09-30 | $0.00 10-Q · filed 2014-11-13 | $0.00 10-Q · filed 2014-11-13 | ||
| 2012-12-31 | $0.00 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |